NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Multiple Technology Appraisal (MTA)

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab for the treatment of rheumatoid arthritis (review of TA guidance 130, 186, 224, 234 and part review of TA guidance 225 and 247)

Please sign and return to:

Jenna Byers, Technology Appraisal Administrator
Email: TACommC@nice.org.uk
Fax: +44 (0)20 7061 9760
Post: NICE, Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT

I confirm that:

- I agree with the content of the statement submitted by the National Rheumatoid Arthritis Society (NRAS) and consequently I will not be submitting a personal statement.

Name: AILSA BOSWORTH

Signed: [redacted]

Date: 18th MARCH 2013